| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $26,593,897 ) (Continued on the next page) |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 001 | 18 | NIH | 11/17/2022 | $607,963 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI170214 | Developing Durable, Env-Boosted CAR T Cells for HIV Cure | 000 | 1 | NIH | 11/2/2022 | $893,464 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA277133 | Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies | 000 | 1 | NIH | 11/15/2022 | $413,415 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI167004 | In Vivo Gene Editing of B cells with NICE-AAV Vectors | 000 | 3 | NIH | 11/25/2022 | $125,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI167004 | In Vivo Gene Editing of B cells with NICE-AAV Vectors | 000 | 3 | NIH | 11/25/2022 | $646,804 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | F32CA254805 | Reactivation of an early embryonic program in FSHD and cancer | 000 | 4 | NIH | 11/3/2022 | $69,802 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R37CA234488 | Role of tumor cell cluster-induced signaling in breast cancer metastasis | 001 | 5 | NIH | 11/30/2022 | $362,340 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA243328 | Tumor-specific autoantibodies for SCLC early detection | 000 | 5 | NIH | 11/1/2022 | $396,575 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI150500 | Mathematical modeling of optimal therapeutic combinations for HIV cure | 000 | 5 | NIH | 11/21/2022 | $465,886 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R37CA230617 | Hormone signaling and translation control in advanced prostate cancer | 000 | 6 | NIH | 11/30/2022 | $390,546 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | P01AI138212 | Expansion and targeted maturation of germline HIV-1 bNAb-associated BCRs | 000 | 6 | NIH | 11/17/2022 | $1,900,554 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA226172 | Developing Bioinformatic and Microfluidic Single Cell Methods for Studying Intratumoral Heterogeneity in Acute Myeloid Leukemia | 000 | 6 | NIH | 11/23/2022 | $564,579 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI141435 | Tissue Regulatory T Cells in Mucosal Infection | 000 | 6 | NIH | 10/18/2022 | $635,939 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 000 | 18 | NIH | 11/21/2022 | $6,336,305 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 000 | 18 | NIH | 11/21/2022 | $400,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 001 | 18 | NIH | 11/17/2022 | $241,107 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA276308 | Transcriptional-translational conflict in bladder epithelial homeostasis and cancer | 000 | 1 | NIH | 11/28/2022 | $588,061 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 000 | 18 | NIH | 11/21/2022 | $9,326,734 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R21HD107577 | Erythrocyte fatty acids and risk of endometriosis | 000 | 1 | NIH | 11/10/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UG3DA057032 | ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation | 000 | 1 | NIH | 12/6/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R25LM014210 | SeattleStatSummer for Biomedical Data Science Research Training | 000 | 1 | NIH | 12/2/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R25LM014210 | SeattleStatSummer for Biomedical Data Science Research Training | 000 | 1 | NIH | 12/2/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R21NS124191 | Discovery of sensorimotor connectivity mechanisms in a continuous topographic map | 001 | 2 | NIH | 11/15/2022 | $4,431 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | U54CA274374 | Understanding adenoma progression: Interplay among tissue microenvironment, clonal architecture, and gut microbiome | 000 | 1 | NIH | 11/2/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R35GM140823 | Mechanisms of transcriptional regulation and transcription factor specificity | 001 | 2 | NIH | 11/7/2022 | $178,837 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | K99GM138920 | Genome-wide mechanisms and dynamics of ATP-dependent chromatin remodeling complexes | 001 | 2 | NIH | 10/30/2022 | $15,228 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | K99GM140251 | Molecular impediments to fate-specifying pioneer factor activity during development | 001 | 2 | NIH | 11/4/2022 | $9,205 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01NS119650 | Defining cellular states of quiescence in human brain tumors | 001 | 3 | NIH | 11/16/2022 | $82,644 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R35GM139429 | Molecular mechanisms and functions of global chromatin control | 000 | 3 | NIH | 11/9/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R21AI169085 | Integrating T cell receptor features with gene expression profiles to define T cell specificity and differentiation | 001 | 2 | NIH | 10/14/2022 | $1 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | K99NS121595 | Mechanisms of Target-Specific Axon Regeneration | 001 | 2 | NIH | 11/30/2022 | $2,958 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UE5CA254170 | Scalable multi-mode education to increase use of ITCR tools by diverse analysts | 002 | 3 | NIH | 11/30/2022 | $861,118 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R37CA246703 | Planning Advance Care Together (PACT) to Improve Engagement in Advance Care Planning among Advanced Cancer Patients | 000 | 4 | NIH | 11/21/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UH3CA218909 | ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement | 000 | 6 | NIH | 11/15/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | U54CA242977 | Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center | 000 | 5 | NIH | 10/18/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | K08CA241296 | Developing an intervention to improve follow-up of abnormal fecal immunochemical test results in a safety-net population using a mixed methods approach | 000 | 5 | NIH | 11/29/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01NS115974 | Membrane Curvature Sensing Mechanisms for Synaptic Vesicle Endocytosis | 004 | 4 | NIH | 11/28/2022 | $175,033 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01NS115974 | Membrane Curvature Sensing Mechanisms for Synaptic Vesicle Endocytosis | 004 | 4 | NIH | 11/28/2022 | $72,640 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | F31AI150163 | Evolutionary dynamics of antibody affinity maturation | 000 | 4 | NIH | 10/14/2022 | -$17,497 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA252874 | Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain | 000 | 4 | NIH | 11/30/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R37CA234488 | Role of tumor cell cluster-induced signaling in breast cancer metastasis | 000 | 4 | NIH | 11/22/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R35GM133441 | Investigating chromatin mechanisms using viral systems | 004 | 5 | NIH | 11/18/2022 | $0 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01AI147877 | Discovery and Characterization of Capsid-Targeting Lentiviral Restriction Factors | 000 | 5 | NIH | 11/16/2022 | -$312,584 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R13OD024033 | Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference | 001 | 6 | NIH | 11/28/2022 | $54,601 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | T32AI118690 | Training Program in Infectious Diseases in the Immunocompromised Host | 002 | 8 | NIH | 11/17/2022 | $474,512 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | T32AI118690 | Training Program in Infectious Diseases in the Immunocompromised Host | 003 | 8 | NIH | 11/21/2022 | $269,997 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | T32AI118690 | Training Program in Infectious Diseases in the Immunocompromised Host | 001 | 8 | NIH | 11/4/2022 | -$269,997 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | T32AI118690 | Training Program in Infectious Diseases in the Immunocompromised Host | 000 | 8 | NIH | 11/4/2022 | -$474,512 |
| | 2023 | 2022 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | U54CA132381 | 2/2 Partnership for the Advancement of Cancer Research: NMSU & Fred Hutch | 000 | 16 | NIH | 11/22/2022 | $0 |
|
